The ICM helps healthcare professionals use better tools for risk stratification and diagnosis. Credit: Sasin Tipchai from Pixabay.

Medical technology company Biotronik has announced the first global implant of its BIOMONITOR IV implantable cardiac monitor (ICM) with artificial intelligence (AI).

Montefiore Einstein Medicine Professor Dr Luigi Di Biase carried out the first procedure with the system.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Di Biase said: “The data shows that these new features have the potential to reduce false positive alerts for our patients and allow us to focus on actionable events, providing more efficient care.”

The ICM integrates the company’s SmartECG technology with AI to lower all false positive detections by 86% and preserve 98% of true episodes.

It is claimed to be the only ICM that can differentiate between premature atrial contractions and premature ventricular contractions, helping healthcare professionals to use better tools for risk stratification and diagnosis.

The ICM has a long battery life and wireless connectivity, which allows seamless data transmission and remote monitoring, enabling to avoid frequent in-person clinic visits.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, the company provides a simple electronic health record data integration capability, which helps enhance the workflow of a clinic significantly.

In April this year, Biotronik announced that its MATRIX study demonstrated the high detection accuracy of DX single-lead implantable cardioverter-defibrillator (ICD) systems for atrial fibrillation in single-chamber ICD patients.

Biotronik offers cardiovascular, endovascular and neuromodulation solutions for patients with heart and blood vessel diseases as well as chronic pain.

Based in Berlin, Germany, the company conducts operations in more than 100 countries.